<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.117455</article-id><article-id pub-id-type="publisher-id">ACM-43988</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210700000_85798276.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  乳腺癌微环境中γδT淋巴细胞的研究进展
  Research Progress of γδT Lymphocytes in Breast Cancer Microenvironment
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>向荣</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>张</surname><given-names>艳丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>丁</surname><given-names>勇</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>马</surname><given-names>春玲</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>临沂市妇幼保健院，山东 临沂</addr-line></aff><aff id="aff3"><addr-line>山东医学高等专科学校，山东 临沂</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>02</day><month>07</month><year>2021</year></pub-date><volume>11</volume><issue>07</issue><fpage>3138</fpage><lpage>3144</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  为理解γδT淋巴细胞在乳腺癌微环境中的作用机制，本文检索了近几年来发表的有关文献，综述了γδT淋巴细胞在乳腺癌细胞水平、小鼠模型体内水平，以及在肿瘤治疗方面的临床研究，论证了γδT淋巴细胞具有抗肿瘤和促肿瘤的双重活性与其亚型的相关性，为乳腺癌的有效治疗提供理论和实验依据。
   In order to understand the role of γδT lymphocytes in the microenvironment of breast cancer, this article retrieved articles on γδT lymphocytes published in domestic and foreign journals over the past years, and summarized the role of γδT lymphocytes in breast cancer cells, in vivo on mouse models, and clinical studies on tumor treatment. We have demonstrated that γδT lymphocytes have dual anti-tumor and tumor-promoting activities related to their subtypes, providing theoretical and experimental basis for effective treatment of breast cancer.
 
</p></abstract><kwd-group><kwd>乳腺癌，肿瘤微环境，γδT淋巴细胞，免疫治疗, Breast Cancer</kwd><kwd> Tumor Microenvironment</kwd><kwd> γδT Lymphocytes</kwd><kwd> Immunotherapy</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>为理解γδT淋巴细胞在乳腺癌微环境中的作用机制，本文检索了近几年来发表的有关文献，综述了γδT淋巴细胞在乳腺癌细胞水平、小鼠模型体内水平，以及在肿瘤治疗方面的临床研究，论证了γδT淋巴细胞具有抗肿瘤和促肿瘤的双重活性与其亚型的相关性，为乳腺癌的有效治疗提供理论和实验依据。</p></sec><sec id="s2"><title>关键词</title><p>乳腺癌，肿瘤微环境，γδT淋巴细胞，免疫治疗</p></sec><sec id="s3"><title>Research Progress of γδT Lymphocytes in Breast Cancer Microenvironment<sup> </sup></title><p>Xiangrong Yang<sup>1</sup>, Yanli Zhang<sup>1</sup>, Yong Ding<sup>1</sup>, Chunling Ma<sup>2*</sup></p><p><sup>1</sup>Women and Children Health Care Center of Linyi City, Linyi Shandong</p><p><sup>2</sup>Shandong Medical College, Linyi Shandong</p><p><img src="//html.hanspub.org/file/36-1572374x4_hanspub.png?20210721082857892" /></p><p>Received: Jun. 15<sup>th</sup>, 2021; accepted: Jul. 5<sup>th</sup>, 2021; published: Jul. 20<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/36-1572374x5_hanspub.png?20210721082857892" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>In order to understand the role of γδT lymphocytes in the microenvironment of breast cancer, this article retrieved articles on γδT lymphocytes published in domestic and foreign journals over the past years, and summarized the role of γδT lymphocytes in breast cancer cells, in vivo on mouse models, and clinical studies on tumor treatment. We have demonstrated that γδT lymphocytes have dual anti-tumor and tumor-promoting activities related to their subtypes, providing theoretical and experimental basis for effective treatment of breast cancer.</p><p>Keywords:Breast Cancer, Tumor Microenvironment, γδT Lymphocytes, Immunotherapy</p><disp-formula id="hanspub.43988-formula26"><graphic xlink:href="//html.hanspub.org/file/36-1572374x7_hanspub.png?20210721082857892"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/36-1572374x8_hanspub.png?20210721082857892" /> <img src="//html.hanspub.org/file/36-1572374x9_hanspub.png?20210721082857892" /></p></sec><sec id="s5"><title>1. 引言</title><p>根据2018年的全球癌症统计数据，乳腺癌新发病率居于全球总人口癌症发病率的第二位，占癌症总人数的11.6%。而在全球女性癌症中，乳腺癌占据了1/4的数量。中国女性乳腺癌发病率相对于全球发病率来说虽然很低，但发病率的增长速度却是全球发病率的两倍 [<xref ref-type="bibr" rid="hanspub.43988-ref1">1</xref>]。因此，临床上仍然迫切需求更有效、更具针对性的治疗方法、以及更可靠的预后指标。而来越多的研究表明，肿瘤微环境中的组分在肿瘤的进展和转移中起着重要的作用 [<xref ref-type="bibr" rid="hanspub.43988-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.43988-ref3">3</xref>]。微环境中的各种组分，如成纤维细胞、肿瘤基质成分和各种免疫细胞对肿瘤细胞的增殖和抑制作用各不相同。其中的γδT淋巴细胞作为免疫系统的成员，不同亚型对肿瘤的作用截然不同 [<xref ref-type="bibr" rid="hanspub.43988-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.43988-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.43988-ref6">6</xref>]，从而引起了研究者的广泛关注。本文总结了近年来报道的γδT淋巴细胞在乳腺癌微环境中作用机制的研究结果，以及γδT淋巴细胞的免疫功能及其在乳腺癌免疫治疗的临床应用进行了综述。</p></sec><sec id="s6"><title>2. γδT淋巴细胞免疫功能的研究</title><p>T淋巴细胞根据TCR的不同可分为αβT淋巴细胞和γδT淋巴细胞。γδT淋巴细胞在血液和淋巴组织中占CD3<sup>+</sup>T细胞的0.5%~16% (平均为4%)，在健康成人肠道上皮中占10%~30%。根据γδＴ细胞表达的Vγ和Vδ功能区的不同可将其分为两个主要亚群，即Vδ1<sup>+</sup>T细胞和Vδ2<sup>+</sup>T细胞。前者主要存在于肠道和皮肤中，后者主要存在于外周血中。Vδ2<sup>+</sup>T淋巴细胞又可细分为Vγ9<sup>+</sup>Vδ2<sup>+</sup>的先天性亚群和Vγ9<sup>−</sup>Vδ2<sup>+</sup>适应性亚群 [<xref ref-type="bibr" rid="hanspub.43988-ref5">5</xref>] [<xref ref-type="bibr" rid="hanspub.43988-ref7">7</xref>]。</p><p>由于γδT淋巴细胞上多数不表达CD4或CD8共受体 [<xref ref-type="bibr" rid="hanspub.43988-ref6">6</xref>]，因此对抗原的识别并不受MHC分子约束。由于其表达有自然杀伤受体(如NKG2D等)，因此有人认为γδT淋巴细胞是先天免疫系统和适应性免疫系统之间的联结点 [<xref ref-type="bibr" rid="hanspub.43988-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.43988-ref8">8</xref>]。γδTCR可识别多种抗原，如肽、未加工蛋白质、硫酸盐和磷脂等 [<xref ref-type="bibr" rid="hanspub.43988-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.43988-ref9">9</xref>]。磷酸化抗原是一类被广泛报道的γδT淋巴细胞刺激因子 [<xref ref-type="bibr" rid="hanspub.43988-ref10">10</xref>]。常见的焦磷酸分子如微生物产生的(e)-4-羟基-3-甲基-2-苯基焦磷酸(HMBPP)和转化真核细胞产生的异戊焦磷酸(IPP)等。γδT淋巴细胞对这些分子的识别是它发挥抗微生物入侵和抗肿瘤免疫作用的关键。由于γδT淋巴细胞活化不依赖于抗原提成，因此有人认为它们能迅速启动免疫应答 [<xref ref-type="bibr" rid="hanspub.43988-ref7">7</xref>]。γδT细胞可在与靶细胞接触时释放穿孔素和颗粒酶等物质，介导靶细胞的凋亡，也能够释放多种细胞因子发挥免疫调节作用，发挥抗肿瘤作用。当γδT细胞与肿瘤细胞结合时，其表面的CD16分子能与靶细胞表面单克隆抗体的Fc段相结合，介导ADCC效应杀伤与其结合的肿瘤细胞。另外，γδT细胞还可通过诱导凋亡发挥抗肿瘤作用 [<xref ref-type="bibr" rid="hanspub.43988-ref11">11</xref>]。但是也有文献报道，产生IL-17的γδT细胞加强了中性粒细胞的聚集，从而通过抑制CD8<sup>+</sup>T细胞功能促进了乳腺癌的转移 [<xref ref-type="bibr" rid="hanspub.43988-ref12">12</xref>]。</p></sec><sec id="s7"><title>3. 外周血来源γδT淋巴细胞抑瘤作用的体外研究</title><p>早期的体外研究表明，γδT淋巴细胞在乳腺癌细胞株中具有抗肿瘤活性。Bank [<xref ref-type="bibr" rid="hanspub.43988-ref13">13</xref>] 等人的研究证明来源于正常人外周血的Vγ9Vδ2<sup>+</sup>T细胞对乳腺癌MCF-7细胞株具有细胞毒性。郭 [<xref ref-type="bibr" rid="hanspub.43988-ref14">14</xref>] 等也在研究中发现，来自健康供体外周血的γδT淋巴细胞通过体外扩增后，对MCF-7、T-47d以及MAD-MB-231三种乳腺癌细胞株均具有溶细胞作用。更重要的是，这种溶细胞作用仅作用于癌细胞，而对正常细胞无效。当在共培养体系中加入了中和性的γδTCR抗体后，溶细胞作用下降了75%，表明γδTCR分子对溶解癌细胞发挥了关键作用。然而，是否存在γδTCR抗体诱导凋亡，进而导致γδT淋巴细胞毒性降低的现象并未得到验证。进一步的体外实验表明，体外小鼠外周血来源的γδT淋巴细胞对肿瘤细胞(三阴性4T1乳腺癌细胞系)具有细胞毒性，而对非恶性成纤维细胞无细胞毒性 [<xref ref-type="bibr" rid="hanspub.43988-ref15">15</xref>]。但是，人类γδT亚群是否有相似作用还待进一步验证。</p><p>研究发现γδT淋巴细胞针对不同亚型的乳腺癌细胞的作用是不同的。Aggarwal等将人外周血来源的γδT淋巴细胞与肿瘤细胞共同培养时观察到，肿瘤细胞的存活和增殖受到抑制，且具有剂量依赖性。在MCF-7、HER2<sup>+</sup>SKBR7和ER-MDA-MB231都观察到这种现象，而BRCA-MZ01细胞株(ER/PR+)的观察则恰恰相反。进一步研究发现，敏感细胞系中表达MICAa/b，而在耐药细胞系中则未见表达。此外，细胞间粘附分子1 (ICAM1)在敏感细胞系中表达上调，而在耐药细胞系中表达下调，表明这些分子在γδT淋巴细胞的细胞毒性中可能发挥作用 [<xref ref-type="bibr" rid="hanspub.43988-ref16">16</xref>]。在其它癌症的研究中发现，ICAM1是Vγ9<sup>+</sup>Vδ2<sup>+</sup>T淋巴细胞的共刺激配体，在内皮蛋白C受体依赖性识别通路中发挥作用 [<xref ref-type="bibr" rid="hanspub.43988-ref17">17</xref>]。Aggarwal还发现γδT淋巴细胞可以抑制血管生成信号通路并增强肿瘤细胞凋亡，敏感细胞系的ATK、ERK等信号通路磷酸化减少，但在耐药细胞系中则是增加的，而这些通路与细胞存活密切相关 [<xref ref-type="bibr" rid="hanspub.43988-ref16">16</xref>]。</p><p>有研究报道，健康对照组的血液标本(79例)中γδT淋巴细胞的比例是乳腺癌患者血液标本(38例)的1.6倍(P = 0.002)，而乳腺癌患者来源的γδT淋巴细胞体外扩增后产生的IL-6和TNF-α明显高于健康对照组的，但IFN-γ却低于健康人(p &lt; 0.05)，同时，与健康对照组相比，癌症组的γδT淋巴细胞释放的颗粒酶B明显减少(p &lt; 0.02)，而颗粒酶B与细胞凋亡有关 [<xref ref-type="bibr" rid="hanspub.43988-ref18">18</xref>]。后续研究发现，γδT淋巴的水平高低与乳腺癌患者的TNM分期呈负相关性 [<xref ref-type="bibr" rid="hanspub.43988-ref19">19</xref>]。证明肿瘤患者外周血的γδT细胞具有免疫抑制功能。</p></sec><sec id="s8"><title>4. 模型鼠体内γδT淋巴细胞抗肿瘤活性的研究</title><p>研究模型鼠体内γδT淋巴细胞对肿瘤作用的报道分为两种类型，一是研究模型鼠体内过继转移的γδT淋巴细胞的作用，二是研究模型鼠体内本身的γδT淋巴细胞在肿瘤中的作用。</p><p>在模型鼠体内过继转移的γδT淋巴细胞的研究中，Beck等人 [<xref ref-type="bibr" rid="hanspub.43988-ref15">15</xref>] 发现，过继转移的γδT淋巴细胞，可以通过TCR而定位于乳腺肿瘤，并证明这种定位方式是肿瘤细胞识别的关键。Aggarwal [<xref ref-type="bibr" rid="hanspub.43988-ref16">16</xref>] 等人的研究发现，当向小鼠体内同时注射人源性γδT淋巴细胞和skbr7或brca-mz01乳腺癌细胞株时，与单独注射乳腺癌细胞株的对照组相比，联合注射人源性γδT淋巴细胞组肿瘤生长慢于对照组，brca-mz01细胞株变化尤为显著，且联合注射组小鼠肿瘤细胞中，与存活、生长有关的信号分子akt、erk和stat3的磷酸化发生下调，与凋亡相关分子则发生显著上调，凋亡细胞数明显高于对照组。另外，血管生成信号分子在联合注射组中也表现为下调，血管生成数量也相应减少。Beck [<xref ref-type="bibr" rid="hanspub.43988-ref15">15</xref>] 等人还报道，在同基因小鼠模型中，4T1乳腺癌细胞系的荷瘤小鼠在接受体外扩增的鼠源性γδT淋巴细胞治疗时，与未经治疗的对照组相比，肿瘤生长显著减低。将人源性γδT淋巴细胞应用于2LMP人乳腺癌细胞系的乳腺癌异种移植小鼠模型时，结果与上述一致。</p><p>在模型鼠体内本身的γδT淋巴细胞对肿瘤作用等研究中，Coffeet [<xref ref-type="bibr" rid="hanspub.43988-ref12">12</xref>] 等人证明，模型鼠脾脏来源的γδT和CD4<sup>+</sup>T淋巴细胞均表达IL-17A，但仅当γδT淋巴细胞缺失时会导致IL-17A和GCSF血清水平降低，从而导致循环中性粒细胞减少，进而促进肿瘤的生长。此外，在该小鼠模型中发现，在肿瘤发生的早期阶段，γδT淋巴细胞的耗竭可减轻肿瘤细胞向肺和淋巴结转移，但对原位肿瘤的生长无影响。以上研究证明不同的γδT淋巴细胞亚型对肿瘤的免疫调节作用是不同的。</p></sec><sec id="s9"><title>5. 肿瘤浸润γδT淋巴细胞促肿瘤作用的体外研究</title><p>研究表明，血液来源的γδT淋巴细胞，主要是Vγ9Vδ2<sup>+</sup>亚型，而乳腺肿瘤来源的肿瘤浸润性淋巴细胞(TILS)中的γδT淋巴细胞主要为γδ1<sup>+</sup>亚型(95%)，占TILS的7.2%~75.7% [<xref ref-type="bibr" rid="hanspub.43988-ref20">20</xref>]。有研究报道，在体外试验中乳腺癌组织来源TILs具有免疫抑制作用，可以抑制免疫初始细胞的增殖，诱导CD4<sup>+</sup>、CD8<sup>+</sup>T细胞的老化 [<xref ref-type="bibr" rid="hanspub.43988-ref20">20</xref>]，并阻断了树突状细胞(DC)的成熟和细胞因子的分泌 [<xref ref-type="bibr" rid="hanspub.43988-ref12">12</xref>]，进而发挥促进肿瘤生长的作用。</p><p>Ye J的研究小组分析了在体外人类肿瘤浸润γδT淋巴细胞的功能，发现其可以诱导被细胞毒性T淋巴细胞识别的细胞发生周期阻滞，与目前研究较广泛的CD4<sup>+</sup> CD25<sup>+</sup>调节性T细胞(Tregs)一样，γδT细胞也可以通过诱导免疫细胞(CD4<sup>+</sup>、CD8<sup>+</sup>T细胞)发生老化从而发挥免疫抑制作用。所以，对具有免疫调节作用的γδT淋巴细胞亚型叫做γδTreg。试验检测发现被诱导老化的淋巴细胞分泌大量的促炎性因子，如IL-6、IFN-γ和TNF-α，同时分泌IL-10和修饰化的TGF-β1，均具有免疫负性调节的作用 [<xref ref-type="bibr" rid="hanspub.43988-ref21">21</xref>]。Peng的研究小组还研究了81例乳腺癌患者的肿瘤组织与配对的正常组织之间的差异，发现γδT淋巴细胞的数量与TNM分期、淋巴结转移和HER2的表达呈正相关。肿瘤组织中γδT淋巴细胞数量越高，无复发生存率越低，总生存率也越低 [<xref ref-type="bibr" rid="hanspub.43988-ref20">20</xref>]。这提示肿瘤微环境中的γδT淋巴细胞可能促进肿瘤生长，且与癌症的亚型无关。</p><p>在一项针对三阴性乳腺癌的研究中，Hidalgo等 [<xref ref-type="bibr" rid="hanspub.43988-ref22">22</xref>] 证明，与正常乳腺组织相比，这些肿瘤组织含有更高比例的γδT淋巴细胞。他们比较了乳腺导管癌组织和髓样癌组织，发现两种肿瘤类型之间γδT淋巴细胞的分布有明显差异；在乳腺导管癌组织中γδT淋巴细胞常位于基质中，而在髓样癌组织中γδT淋巴细胞多分布于实质和肿瘤细胞周围。</p></sec><sec id="s10"><title>6. 肿瘤浸润的γδT淋巴细胞亚型的促肿瘤作用的模型鼠研究</title><p>上述两位研究者通过小鼠模型体内实验验证了体外实验的结果。Peng [<xref ref-type="bibr" rid="hanspub.43988-ref23">23</xref>] 的团队在模型鼠上首先证实了乳腺肿瘤来源的γδTreg淋巴细胞能够抑制CD8<sup>+</sup>T细胞杀伤肿瘤细胞，表现出促肿瘤生长的作用；进一步研究证实γδTreg淋巴细胞可以诱导初始和效应性T细胞衰老，进而抑制功能性CD4<sup>+</sup>T细胞增殖，而TLR8信号可以对衰老进行阻断。但目前大多数对γδT淋巴细胞的体内研究都是在小鼠模型上进行的，而人与鼠的γδTreg淋巴细胞亚群及特性存在一定差异，动物体内研究的结果在人体是否相同仍待进一步验证。</p><p>体内外研究表明，外周血来源的II型γδT淋巴细胞表现出抗瘤抑瘤作用，而肿瘤微环境中的I型γδT淋巴细胞更多的表现出促瘤的特性。然而，Zhao的研究小组则认为，γδT淋巴细胞功能表现出一定程度的功能可塑性。不管它们的γδ链的构型如何，在各种细胞因子的刺激作用下，它们可以在功能上极化成不同的亚型 [<xref ref-type="bibr" rid="hanspub.43988-ref8">8</xref>]。因此，如何对γδT淋巴细胞进行诱导，降低其免疫抑制特性，更好的发挥其抗肿瘤作用，具有重要的研究意义。Peng的研究小组已经成功通过TLR8配体逆转γδTreg对免疫T细胞老化的诱导，进而提高乳腺癌微环境的正向免疫调节，增强抗肿瘤活性。</p></sec><sec id="s11"><title>7. γδT淋巴细胞抗肿瘤免疫治疗的临床研究</title><p>在乳腺癌治疗中，双膦酸盐是近年开始应用的一种治疗方式，其机制主要是利用双膦酸盐激活Vγ9Vδ2<sup>+</sup>T淋巴细胞，增强其促凋亡作用从而发挥其抗肿瘤作用 [<xref ref-type="bibr" rid="hanspub.43988-ref24">24</xref>]。膦酸盐预处理还能通过提高Vγ9Vδ2<sup>+</sup>T淋巴细胞与肿瘤细胞的附着强度，增强其溶瘤效果。在体外实验中，双膦酸盐还表现出刺激Vγ9Vδ2<sup>+</sup>T淋巴细胞增殖的作用。Benzaid [<xref ref-type="bibr" rid="hanspub.43988-ref25">25</xref>] 等研究证明，在体外和体内小鼠模型中，唑来膦酸盐可引起Vγ9Vδ2<sup>+</sup>T淋巴细胞活化增殖，并增强其细胞毒作用。</p><p>双膦酸盐于增强Vγ9Vδ2<sup>+</sup>T淋巴细胞反应性，对于其临床治疗效果有着重要意义。然而在多种肿瘤的临床试验中发现，Vγ9Vδ2<sup>+</sup>T淋巴细胞反应率仅为21%。因此，要达到一定的治疗量就必须对其进行体内或体外的扩增 [<xref ref-type="bibr" rid="hanspub.43988-ref26">26</xref>]。Sugie等在进行体外扩增法时发现，在唑来膦酸盐和IL-2存在的情况下，Vγ9Vδ2<sup>+</sup>T淋巴细胞的增殖以及IFN-γ和TNF-α的产生与患者血液中Vγ9Vδ2<sup>+</sup>T细胞的初始频率相关，这说明当血液循环中Vγ9Vδ2<sup>+</sup>T淋巴细胞数量较低时，免疫治疗的疗效有限。然而，在唑来膦酸盐和IL-2中加入IL-18时，无论Vγ9Vδ2<sup>+</sup>T淋巴细胞的初始频率如何，细胞增殖反应和细胞因子的产生都会增强。因此，这种方法对早期和晚期乳腺癌的治疗有重要意义 [<xref ref-type="bibr" rid="hanspub.43988-ref19">19</xref>]。双膦酸盐和Vγ9Vδ2<sup>+</sup>T淋巴细胞联合应用可能在乳腺癌转移性骨疾病中有较高的临床应用价值 [<xref ref-type="bibr" rid="hanspub.43988-ref27">27</xref>]。</p><p>有研究表明，γδT淋巴细胞联合曲妥珠单抗治疗HER2<sup>+</sup>乳腺癌细胞株，相较于单用γδT淋巴细胞治疗组和单用曲妥珠单抗治疗组的效率更高，在动物实验也得到验证 [<xref ref-type="bibr" rid="hanspub.43988-ref28">28</xref>]。如前所述，体外和体内均证明，通过控制γδT淋巴细胞中的TLR8配体可以逆转CD4<sup>+</sup>和CD8<sup>+</sup>T细胞以及DC的衰老，进而达到抑制γδ1<sup>+</sup>T细胞促瘤作用的目的，或许可以成为全新而有力地肿瘤免疫治疗方案，为肿瘤的治疗提供新思路。另外，γδT淋巴细胞还与乳腺癌的临床病理指标有相关性，可以作为一种肿瘤预后的预测性生物标记物。</p></sec><sec id="s12"><title>8. 结论与展望</title><p>总而言之，γδT淋巴细胞作为一种特殊的免疫细胞，在肿瘤免疫治疗有着潜在的、不可估量的应用价值。这与其识别抗原的非MHC限制性以及反应的快速性是密不可分的。其对肿瘤的抑制和杀伤作用可以通过直接细胞毒性、分泌细胞因子刺激其他免疫组份、抑制肿瘤组织血管生成等方式来实现。然而，γδT淋巴细胞在乳腺癌肿的作用又受到肿瘤微环境等多方面因素的影响。发挥γδT淋巴细胞对乳腺癌的抑制作用，不仅要考虑到不同亚型的作用不同，以及不同免疫组份之间的相互作用，还要考虑到肿瘤微环境的诱导作用。如何最大程度的发挥γδT淋巴细胞的潜力使其服务于临床，仍有待于研究者进一步探究。</p></sec><sec id="s13"><title>基金项目</title><p>山东省自然基金面上项目：乳腺癌微环境中γδTreg细胞诱导免疫老化及其逆转的机制探讨(ZR2017MH059)。</p></sec><sec id="s14"><title>文章引用</title><p>杨向荣,张艳丽,丁 勇,马春玲. 乳腺癌微环境中γδT淋巴细胞的研究进展Research Progress of γδT Lymphocytes in Breast Cancer Microenvironment[J]. 临床医学进展, 2021, 11(07): 3138-3144. https://doi.org/10.12677/ACM.2021.117455</p></sec><sec id="s15"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.43988-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Bray, F., Ferlay, J., Soerjiomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancer in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. &lt;br&gt;https://doi.org/10.3322/caac.21492</mixed-citation></ref><ref id="hanspub.43988-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Roxburgh, C.S. and McMillan, D.C. (2012) The Role of the in Situ Local Inflammatory Response in Predicting Recurrence and Survival in Patients with Primary Operable Colorectal Cancer. Cancer Treatment Reviews, 38, 451-466.  
&lt;br&gt;https://doi.org/10.1016/j.ctrv.2011.09.001</mixed-citation></ref><ref id="hanspub.43988-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Hanahan, D. and Weinberg, R.A. (2011) Hallmarks of Cancer: The Next Generation. Cell, 144, 646-674.  
&lt;br&gt;https://doi.org/10.1016/j.cell.2011.02.013</mixed-citation></ref><ref id="hanspub.43988-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Davey, M.S., Willcox, C.R., Joyce, S.P., Ladell, K., Kasatskaya, S.A., McLaren, J.E., et al. (2017) Clonal Selection in the Human Vδ1 T Cell Repertoire Indicates γδ TCR-Dependent Adaptive Immune Surveillance. Nature Communications, 8, Article No. 14760. &lt;br&gt;https://doi.org/10.1038/ncomms14760</mixed-citation></ref><ref id="hanspub.43988-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Davey, M.S., Willcox, C.R., Hunter, S., Kasatskaya, S.A., Remmerswaal, E.B.M., Salim, M., et al. (2018) The Human Vδ2+ T-Cell Compartment Comprises Distinct Innate-Like Vγ9+ and Adaptive Vγ9− Subsets. Nature Communications, 9, Article No. 1760. &lt;br&gt;https://doi.org/10.1038/s41467-018-04076-0</mixed-citation></ref><ref id="hanspub.43988-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Davey, M.S., Willcox, C.R., Baker, A.T., Hunter, S. and Willcox, B.E. (2018) Recasting Human Vδ1 Lymphocytes in an Adaptive Role. Trends in Immunology, 39, 446-459. &lt;br&gt;https://doi.org/10.1016/j.it.2018.03.003</mixed-citation></ref><ref id="hanspub.43988-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Lafont, V., Sanchez, F., Laprevotte, E., Michaud, H.-A., Gros, L., Eliaou, J.-F., et al. (2014) Plasticity of Gammadelta T Cells: Impact on the Antitumor Response. Frontiers in Immunology, 5, Article No. 622.  
&lt;br&gt;https://doi.org/10.3389/fimmu.2014.00622</mixed-citation></ref><ref id="hanspub.43988-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Wu, Y.L., Ding, Y.P., Tanaka, Y., Shen, L.W., Wei, C.H., Minato, N., et al. (2014) γδ T Cells and Their Potential for Immunotherapy. International Journal of Biological Sciences, 10, 119-135. &lt;br&gt;https://doi.org/10.7150/ijbs.7823</mixed-citation></ref><ref id="hanspub.43988-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Ferreira, L.M. (2013) Gammadelta T Cells: Innately Adaptive Immune Cells. International Reviews of Immunology, 32, 223-248. &lt;br&gt;https://doi.org/10.3109/08830185.2013.783831</mixed-citation></ref><ref id="hanspub.43988-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Born, W.K., Reardon, C.L. and O’Brien, R.L. (2006) The Function of γδ T Cells in Innate Immunity. Current Opinion in Immunology, 18, 31-38. &lt;br&gt;https://doi.org/10.1016/j.coi.2005.11.007</mixed-citation></ref><ref id="hanspub.43988-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Dokouhaki, P., Han, M., Joe, B., Li, M., Johnston, M.R., Tsao, M.-S., et al. (2010) Adoptive Immunotherapy of Cancer Using ex Vivo Expanded Human γδ T Cells: A New Approach. Cancer Letters, 297, 126-136.  
&lt;br&gt;https://doi.org/10.1016/j.canlet.2010.05.005</mixed-citation></ref><ref id="hanspub.43988-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Coffelt, S.B., Kersten, K., Doornebal, C.W., Weiden, J., Vrijland, K., Hau, C.-S., et al. (2015) IL-17-Producing γδ T Cells and Neutrophils Conspire to Promote Breast Cancer Metastasis. Nature, 522, 345-348.  
&lt;br&gt;https://doi.org/10.1038/nature14282</mixed-citation></ref><ref id="hanspub.43988-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Bank, I., Book, M., Huszar, M., Baram, Y., Schnirer, I. and Brenner, H. (1993) Vδ2+ γδ T Lymphocytes Are Cytotoxic to the MCF 7 Breast Carcinoma Cell Line and Can Be Detected among the T Cells That Infiltrate Breast Tumors. Clinical Immunology &amp; Immunopathology, 67, 17-24. &lt;br&gt;https://doi.org/10.1006/clin.1993.1040</mixed-citation></ref><ref id="hanspub.43988-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Guo, B.L., Liu, Z., Aldrich, W.A. and Lopez, R.D. (2005) Innate Anti-Breast Cancer Immunity of Apoptosis-Resistant Human γδ-T Cells. Breast Cancer Research &amp; Treatment, 93, 69-175. &lt;br&gt;https://doi.org/10.1007/s10549-005-4792-8</mixed-citation></ref><ref id="hanspub.43988-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Beck, B.H., Kim, H.G., Kim, H., Samuel, S., Liu, Z., Shrestha, R., et al. (2010) Adoptively Transferred ex Vivo expanded γδ-T Cells Mediate in Vivo Antitumor Activity in Preclinical Mouse Models of Breast Cancer. Breast Cancer Research &amp; Treatment, 122, 135-144. &lt;br&gt;https://doi.org/10.1007/s10549-009-0527-6</mixed-citation></ref><ref id="hanspub.43988-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Aggarwal, R., Lu, J., Kanji, S., Das, M., Joseph, M., Lustberg, M.B., et al. (2013) Human Vγ2Vδ2 T Cells Limit Breast Cancer Growth by Modulating Cell Survival-, Apoptosis-Related Molecules and Microenvironment in Tumors. International Journal of Cancer, 133, 2133-2144. &lt;br&gt;https://doi.org/10.1002/ijc.28217</mixed-citation></ref><ref id="hanspub.43988-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Willcox, C.R., Pitard, V., Netzer, S., Couzi, L., Salim, M., Silberzahn, T., et al. (2012) Cytomegalovirus and Tumor Stress Surveillance by Binding of a Human γδ T Cell Antigen Receptor to Endothelial Protein C Receptor. Nature Immunology, 13, 872-879. &lt;br&gt;https://doi.org/10.1038/ni.2394</mixed-citation></ref><ref id="hanspub.43988-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Gaafar, A., Aljurf, M.D., Al-Sulaiman, A., Iqniebi, A., Manogaran, P.S., Mohamed, G.E.H., et al. (2009) Defective γδ T-Cell Function and Granzyme B Gene Polymorphism in a Cohort of Newly Diagnosed Breast Cancer Patients. Experimental Hematology, 37, 838-848. &lt;br&gt;https://doi.org/10.1016/j.exphem.2009.04.003</mixed-citation></ref><ref id="hanspub.43988-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sugie, T., Murata-Hirai, K., Iwasaki, M., Morita, C.T., Li, W., Okamura, H., et al. (2013) Zoledronic Acid-Induced Expansion of γδ T Cells from Early-Stage Breast Cancer Patients: Effect of IL-18 on Helper NK Cells. Cancer Immunology Immunotherapy, 62, 677-687. &lt;br&gt;https://doi.org/10.1007/s00262-012-1368-4</mixed-citation></ref><ref id="hanspub.43988-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Ma, C., Zhang, Q., Ye, J., Wang, F., Zhang, Y., Wevers, E., et al. (2012) Tumor-Infiltrating γδ T Lymphocytes Predict Clinical Outcome in Human Breast Cancer. Journal of Immunology, 189, 5029-5036.  
&lt;br&gt;https://doi.org/10.4049/jimmunol.1201892</mixed-citation></ref><ref id="hanspub.43988-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Ye, J., Ma, C., Hsueh, E.C., Eickhoff, C.S., Zhang, Y., Varvares, M.A., et al. (2013) Tumor-Derived γδ Regulatory T Cells Suppress Innate and Adaptive Immunity through Theinduction of Immunosenescence. Journal of Immunology, 190, 2403-2414. &lt;br&gt;https://doi.org/10.4049/jimmunol.1202369</mixed-citation></ref><ref id="hanspub.43988-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Hidalgo, J.V., Bronsert, P., Orlowska-Volk, M., Díaz, L.B., Stickeler, E., Werner, M., et al. (2014) Histological Analysis of γδ T Lymphocytes Infiltrating Human Triple-Negative Breast Carcinomas. Frontiers in Immunology, 5, Article No. 632. &lt;br&gt;https://doi.org/10.3389/fimmu.2014.00632</mixed-citation></ref><ref id="hanspub.43988-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Peng, G., Wang, H.Y., Peng, W., Kiniwa, Y., Seo, K.H., Wang, R.-F., et al. (2007) Tumor-Infiltrating γδ T Cells Suppress T and Dendritic Cell Function via Mechanisms Controlled by a Unique Toll-Like Receptor Signaling Pathway. Immunity, 27, 334-348. &lt;br&gt;https://doi.org/10.1016/j.immuni.2007.05.020</mixed-citation></ref><ref id="hanspub.43988-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Hamilton, E., Clay, T.M. and Blackwell, K.L. (2011) New Perspectives on Zoledronic Acid in Breast Cancer: Potential Augmentation of Anticancer Immune Response. Cancer Investigation, 29, 533-541.  
&lt;br&gt;https://doi.org/10.3109/07357907.2011.605413</mixed-citation></ref><ref id="hanspub.43988-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Benzaid, I., Monkkonen, H., Stresing, V., Bonnelye, E., Green, J., Mönkkönen, J., et al. (2011) High Phosphoantigen Levels in Bisphosphonate-Treated Human Breast Tumors Promote Vγ9Vδ2 T-Cell Chemotaxis and Cytotoxicity in Vivo. Cancer Research, 71, 4562-4572. &lt;br&gt;https://doi.org/10.1158/0008-5472.CAN-10-3862</mixed-citation></ref><ref id="hanspub.43988-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, Y., Niu, C. and Cui, J. (2018) Gamma-Delta (γδ) T Cells: Friend or Foe in Cancer Development. Journal of Translational Medicine, 16, Article No. 3. &lt;br&gt;https://doi.org/10.1186/s12967-017-1378-2</mixed-citation></ref><ref id="hanspub.43988-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Zysk, A., DeNichilo, M.O., Panagopoulos, V., Zinonos, I., Liapis, V., Hay, S., et al. (2017) Adoptive Transfer of ex Vivo Expanded Vγ9Vδ2 T Cells in Combination with Zoledronic Acid Inhibits Cancer Growth and Limits Osteolysis in a Murine Model of Osteolytic Breast Cancer. Cancer Letters, 86, 141-150.  
&lt;br&gt;https://doi.org/10.1016/j.canlet.2016.11.013</mixed-citation></ref><ref id="hanspub.43988-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Capietto, A.H., Martinet, L. and Fournie, J.J. (2011) Stimulated Gammadelta T Cells Increase the in Vivo Efficacy of Trastuzumab in HER2+ Breast Cancer. Journal of Immunology, 187, 1031-1038.  
&lt;br&gt;https://doi.org/10.4049/jimmunol.1100681</mixed-citation></ref></ref-list></back></article>